Prior to joining Amgen, Ron was a Research Investigator at SSCI, Inc. where his responsibilities included crystal form screening activities and stabilization of amorphous systems. Ron joined Amgen’s Pharmaceutical Research & Development (PR&D) – Preformulation organization in 2006 where his responsibilities ranged from developing preclinical formulations to identifying crystal forms for clinical development. From 2011 to 2015, he led the Amgen San Francisco Preformulation Group supporting local site early discovery programs from discovery through candidate selection.
In 2015, Ron relocated to Amgen Thousand Oaks where he established and led the Materials Chemistry and Characterization Group within the Drug Product Technologies organization with the remit to engage with product teams and cross functional partners to deliver in-depth understandings of the solid state properties for synthetic molecules, drug products formulated as a solid matrix, and raw materials. In his current role, Ron is a member of the Material Attributes & Technologies function within Attribute Sciences where he is responsible for engaging with stakeholders to advance and apply materials expertise in support of commercialization and patient supply.
Ron earned a PharmD degree from Xavier University of Louisiana and Ph.D. from The University of Michigan in Pharmaceutical Sciences under the direction of Naír Rodriguez-Hornedo, Ph.D.